Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 66 of the 69 references it cites were found in a registry or an index; 39 of the 72 sources its claims cite were checked for support.

Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016

Open access

Abstract

PROBLEM/CONDITION: Candidemia is a bloodstream infection (BSI) caused by yeasts in the genus Candida. Candidemia is one of the most common health care-associated BSIs in the United States, with all-cause in-hospital mortality of up to 30%. PERIOD COVERED: 2012-2016. DESCRIPTION OF SYSTEM: CDC's Emerging Infections Program (EIP), a collaboration among CDC, state health departments, and academic partners that was established in 1995, was used to conduct active, population-based laboratory surveillance for candidemia in 22 counties in four states (Georgia, Maryland, Oregon, and Tennessee) with a combined population of approximately 8 million persons. Laboratories serving the catchment areas were recruited to report candidemia cases to the local EIP program staff. A case was defined as a blood culture that was positive for a Candida species collected from a surveillance area resident during 2012-2016. Isolates were sent to CDC for species confirmation and antifungal susceptibility testing. Any subsequent blood cultures with Candida within 30 days of the initial positive culture in the same patient were considered part of the same case. Trained surveillance officers collected clinical information from the medical chart for all cases, and isolates were sent to CDC for species confirmation and antifungal susceptibility testing. RESULTS: Across all sites and surveillance years (2012-2016), 3,492 cases of candidemia were identified. The crude candidemia incidence averaged across sites and years during 2012-2016 was 8.7 per 100,000 population; important differences in incidence were found by site, age group, sex, and race. The crude annual incidence was the highest in Maryland (14.1 per 100,000 population) and lowest in Oregon (4.0 per 100,000 population). The crude annual incidence of candidemia was highest among adults aged ≥65 years (25.5 per 100,000 population) followed by infants aged <1 year (15.8). The crude annual incidence was higher among males (9.4) than among females (8.0) and was approximately 2 times greater among blacks than among nonblacks (13.7 versus 5.8). Ninety-six percent of cases occurred in patients who were hospitalized at the time of or during the week after having a positive culture. One third of cases occurred in patients who had undergone a surgical procedure in the 90 days before the candidemia diagnosis, 77% occurred in patients who had received systemic antibiotics in the 14 days before the diagnosis, and 73% occurred in patients who had had a central venous catheter (CVC) in place within 2 days before the diagnosis. Ten percent were in patients who had used injection drugs in the past 12 months. The median time from admission to candidemia diagnosis was 5 days (interquartile range [IQR]: 0-16 days). Among 2,662 cases that were treated in adults aged >18 years, 34% were treated with fluconazole alone, 30% with echinocandins alone, and 34% with both. The all-cause, in-hospital case-fatality ratio was 25% for any time after admission; the all-cause in-hospital case-fatality ratio was 8% for <48 hours after a positive culture for Candida species. Candida albicans accounted for 39% of cases, followed by Candida glabrata (28%) and Candida parapsilosis (15%). Overall, 7% of isolates were resistant to fluconazole and 1.6% were resistant to echinocandins, with no clear trends in resistance over the 5-year surveillance period. INTERPRETATION: Approximately nine out of 100,000 persons developed culture-positive candidemia annually in four U.S. sites. The youngest and oldest persons, men, and blacks had the highest incidences of candidemia. Patients with candidemia identified in the surveillance program had many of the typical risk factors for candidemia, including recent surgery, exposure to broad-spectrum antibiotics, and presence of a CVC. However, an unexpectedly high proportion of candidemia cases (10%) occurred in patients with a history of injection drug use (IDU), suggesting that IDU has become a common risk factor for candidemia. Deaths associated with candidemia remain high, with one in four cases resulting in death during hospitalization. PUBLIC HEALTH ACTION: Active surveillance for candidemia yielded important information about the disease incidence and death rate and persons at greatest risk. The surveillance was expanded to nine sites in 2017, which will improve understanding of the geographic variability in candidemia incidence and associated clinical and demographic features. This surveillance will help monitor incidence trends, track emergence of resistance and species distribution, monitor changes in underlying conditions and predisposing factors, assess trends in antifungal treatment and outcomes, and be helpful for those developing prevention efforts. IDU has emerged as an important risk factor for candidemia, and interventions to prevent invasive fungal infections in this population are needed. Surveillance data documenting that approximately two thirds of candidemia cases we

Overview

CoChat Summary

TL;DR

Active population-based surveillance in four U.S. sites during 2012–2016 identified 3,492 candidemia cases, with an average crude incidence of 8.7 per 100,000 population and a 25% all-cause in-hospital case-fatality ratio. Incidence was highest in Maryland, among adults aged ≥65 years and infants, among males, and among blacks; 10% of cases occurred in patients with recent injection drug use.

Key findings

  • Across 2012–2016, 3,492 candidemia cases were identified from 3,235 patients; crude incidence averaged 8.7 per 100,000 population, highest in Maryland (14.1) and lowest in Oregon (4.0).
  • Crude incidence was highest among adults aged ≥65 years (25.5 per 100,000) and infants aged <1 year (15.8), higher among males (9.4) than females (8.0), and approximately twice as high among blacks as nonblacks (13.7 versus 5.8).
  • Common exposures included systemic antibiotics in the 14 days before diagnosis (77%), central venous catheter within 2 days before diagnosis (73%), surgery in the 90 days before diagnosis (33%), and injection drug use in the past 12 months (10%).
  • Candida albicans accounted for 39% of cases, followed by C. glabrata (28%) and C. parapsilosis (15%); 7% of isolates were fluconazole-resistant and 1.6% were echinocandin-resistant. The all-cause in-hospital case-fatality ratio was 25% overall and 8% within <48 hours after a positive culture.

Methods

  • CDC’s Emerging Infections Program conducted active, population-based laboratory surveillance for culture-confirmed candidemia during 2012–2016 in 22 counties across Georgia, Maryland, Oregon, and Tennessee, with a combined surveillance population of approximately 8.06 million persons.
  • A case was a blood culture positive for Candida species from a surveillance-area resident; cultures within 30 days of the initial positive culture in the same patient were considered one episode. Clinical data were abstracted from medical charts, and isolates were sent to CDC for species confirmation and antifungal susceptibility testing.
  • Crude incidence rates per 100,000 population were calculated using U.S. Census Bureau denominators; multivariable negative binomial regression assessed adjusted incidence rate ratios by age, sex, race, and site, and univariable negative binomial regression assessed 5-year trends.

Limitations

  • The paper states that underlying conditions and predisposing factors were extracted from medical charts, which might underestimate certain conditions such as injection drug use that may not be systematically recorded.
  • The paper states that some culture-proven cases might have been missed despite active, audited surveillance, and that blood-culture-based surveillance underestimates invasive candidiasis because blood culture has suboptimal sensitivity, particularly for intra-abdominal candidiasis or infections without blood cultures.
  • The paper states that data came from 22 counties in four states representing 2.5% of the U.S. population and are not nationally representative, and that only five time points were assessed, limiting understanding of long-term trends. No additional limitations are evident beyond those stated.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.15585/mmwr.ss6808a1

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Crude annual candidemia incidence* — four sites, United States, 2012–2016 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years.
FIGURE 1 Crude annual candidemia incidence* — four sites, United States, 2012–2016 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years.CC BY · PubMed Central
FIGURE 2 Crude annual candidemia incidence,* by age — four sites,† United States, 2012–2016 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years. † Georgia, Maryland, Oregon, and Tennessee.
FIGURE 2 Crude annual candidemia incidence,* by age — four sites,† United States, 2012–2016 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years. † Georgia, Maryland, Oregon, and Tennessee.CC BY · PubMed Central
FIGURE 3 Crude annual candidemia incidence,* by sex — four sites,† United States, 2012–2016 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years. † Georgia, Maryland, Oregon, and Tennessee.
FIGURE 3 Crude annual candidemia incidence,* by sex — four sites,† United States, 2012–2016 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years. † Georgia, Maryland, Oregon, and Tennessee.CC BY · PubMed Central
FIGURE 4 Crude annual candidemia incidence,* by race — four sites,† United States, 2012–2016 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years. † Georgia, Maryland, Oregon, and Tennessee.
FIGURE 4 Crude annual candidemia incidence,* by race — four sites,† United States, 2012–2016 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years. † Georgia, Maryland, Oregon, and Tennessee.CC BY · PubMed Central
FIGURE 5 Species* distribution of Candida organisms, by year — four sites,† United States, 2012–2016 * The category “Candida, other species” includes C. allocifferrii, C. bracarensis, C. dubliniensis, C. fermentati, C. guilliermondii, C. kefyr, C. krusei, C. lipolytica, C. lusitaniae, C. metapsilosis, C. orthopsilosis, C. pararugosa, C. pelliculosa, C. rugosa, and C. sojae. † Georgia, Maryland, Oregon, and Tennessee.
FIGURE 5 Species* distribution of Candida organisms, by year — four sites,† United States, 2012–2016 * The category “Candida, other species” includes C. allocifferrii, C. bracarensis, C. dubliniensis, C. fermentati, C. guilliermondii, C. kefyr, C. krusei, C. lipolytica, C. lusitaniae, C. metapsilosis, C. orthopsilosis, C. pararugosa, C. pelliculosa, C. rugosa, and C. sojae. † Georgia, Maryland, Oregon, and Tennessee.CC BY · PubMed Central

Verification

Claims the paper makes

24 Valid · 4 Not valid · 14 Not checked · 118 Own results and interpretations

95 more claims

Create a free account to see all 160 claims and to verify the 5 references still open.

See all claims — free account
  • Probably not a substantial claim. 32
  • It may state two separate claims as one. 40

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

25 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 69 references

Research works printed but not linked: 1

  1. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—third edition [Internet]. CLSI document no. M27–A3. Vol. 27, No. 9. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. https://clsi.org/media/1461/m27a3_sample.pdf

Cited by

See all 198

Metadata

Authors
Toda, M., Williams, S. R., Berkow, E. L., Farley, M. M., Harrison, L. H., Bonner, L., Marceaux, K. M., Hollick, R., Zhang, A. Y., Schaffner, W., Lockhart, S. R., Jackson, B. R., & Vallabhaneni, S.
Affiliations
  • Centers for Disease Control and Prevention (US)
  • Emory University (US)
  • Johns Hopkins University (US)
  • Oregon Health Authority (US)
  • Vanderbilt University (US)
Corresponding author
Toda, Mitsuru
Venue
MMWR Surveillance Summaries
Published
2019-09-27
Volume
68
Issue
8
Pages
1-15
ISSN
  • 1545-8636 (ISSN-L)
  • 1546-0738
OpenAlex
W2976411969
Cited by
198
References
69
Citations by year
2026: 15 · 2025: 34 · 2024: 24 · 2023: 32 · 2022: 36 · 2021: 34 · 2020: 21 · 2019: 2
FWCI
17.82
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • MMWR Surveillance Summaries (publishedVersion, public-domain)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Centers for Disease Control and Prevention
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
Keywords
candidemia, candidemia incidence, Emerging Infections Program, active surveillance, antifungal susceptibility, antifungal resistance, geographic variation in incidence, racial disparities, age and sex differences, hospitalized patients, nosocomial infections, Maryland, Oregon, Tennessee, United States
MeSH terms
Adolescent, Adult, Aged, Candida, Child, Child, Preschool, Culture Media, Female, Humans, Infant, Male, Middle Aged, Population Surveillance, United States, Age Distribution, Sex Distribution, Racial Groups, Young Adult, Candidemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016. https://app.cochat.ai/papers/10.15585/mmwr.ss6808a1
The paper
Toda, M., Williams, S. R., Berkow, E. L., Farley, M. M., Harrison, L. H., Bonner, L., Marceaux, K. M., Hollick, R., Zhang, A. Y., Schaffner, W., Lockhart, S. R., Jackson, B. R., & Vallabhaneni, S. (2019). Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016. MMWR Surveillance Summaries. https://doi.org/10.15585/mmwr.ss6808a1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.